{"commentary":{"count":104,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":51,"x_thread":35,"podcast":15,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05552976\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SUCCESSOR-2","nct_id":"NCT05552976","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=successor-2-nct05552976. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SUCCESSOR-2","arms":[{"description":null,"label":"MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)","type":"EXPERIMENTAL"},{"description":null,"label":"Kd (Carfilzomib + Dexamethasone)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-07-25","type":"ESTIMATED"},"conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":{"count":606,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Mezigdomide","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-09-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoe E, Galvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet. 2026 Jul 18;408(10551):219-233. doi: 10.1016/S0140-6736(26)01088-3. Epub 2026 Jun 14.","pmid":"42289183","type":"DERIVED"}],"start_date":{"date":"2023-01-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","url":"https://clinicaltrials.gov/study/NCT05552976"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/successor-2-nct05552976"}